Cargando…
Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
BACKGROUND: Pulmonary hypertension is a deadly complication of bronchopulmonary dysplasia, the most common pulmonary morbidity of prematurity. Despite these catastrophic consequences, no evidence-based therapies are available for the prevention of pulmonary hypertension in this population. Sildenafi...
Autores principales: | Schneider, Simone, Bailey, Mary, Spears, Tracy, Esther, Charles R., Laughon, Matthew M., Hornik, Christoph P., Jackson, Wesley |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735412/ https://www.ncbi.nlm.nih.gov/pubmed/33317479 http://dx.doi.org/10.1186/s12887-020-02453-7 |
Ejemplares similares
-
Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial
por: Lang, Jason E., et al.
Publicado: (2022) -
In-hospital Outcomes of Premature Infants with Severe Bronchopulmonary Dysplasia
por: Jackson, Wesley, et al.
Publicado: (2017) -
Safety of sildenafil in extremely premature infants: a phase I trial
por: Jackson, Wesley, et al.
Publicado: (2021) -
Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants
por: Samiee-Zafarghandy, Samira, et al.
Publicado: (2015) -
Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension:
a meta-analysis
por: van der Graaf, Marisa, et al.
Publicado: (2019)